Cline Scientific receives Notice of Allowance for StemCART in Europe

Cline Scientific has received communication that the European Patent Office (EPO) intends to grant the patent application related to the StemCART project. The patent application is titled "A method for providing a cartilage implant with chondrocytes".

This notice of upcoming approval (Notice of Allowance) means that the EPO intends to grant the Company's patent application. Once granted, which is anticipated late Q2 or early Q3, Cline can choose which of the 39 EPO member states in which to uphold the patent. 

More about StemCART
StemCART is a preclinical Advanced Therapy Medicinal Product (ATMP) that aims to revolutionize the treatment of cartilage damage for patients worldwide. 

For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com 
Phone: +46 0703585088
 

Cline Scientific AB (publ)                                                 Phone: 031-387 55 55
Argongatan 2 C                                                                   Email: info@clinescientific.com
431 53  MÖLNDAL                                                              Website: www.clinescientific.com

About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline’s unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.